IL99261A - Methods for the synthesis of oligonucleotides with codon triplets with random codon pairs - Google Patents

Methods for the synthesis of oligonucleotides with codon triplets with random codon pairs

Info

Publication number: IL99261A
Authority: IL; Israel
Prior art keywords: codon; codons; column; synthesis; oligonucleotides
Prior art date: 1990-08-24

Application number

IL9926191A

Other languages

English (en)

Hebrew (he)

Other versions

IL99261A0 (en

Original Assignee

Ixsys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-24

Filing date

1991-08-21

Publication date

1996-09-12

1991-08-21 Application filed by Ixsys Inc filed Critical Ixsys Inc

1992-07-15 Publication of IL99261A0 publication Critical patent/IL99261A0/xx

1996-09-12 Publication of IL99261A publication Critical patent/IL99261A/en

Links

108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 99
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title claims abstract description 69
238000000034 method Methods 0.000 title claims abstract description 53
230000002194 synthesizing effect Effects 0.000 title claims abstract description 18
108020004705 Codon Proteins 0.000 title description 174
238000006243 chemical reaction Methods 0.000 claims abstract description 92
239000000178 monomer Substances 0.000 claims abstract description 89
238000005859 coupling reaction Methods 0.000 claims abstract description 46
230000008878 coupling Effects 0.000 claims abstract description 31
238000010168 coupling process Methods 0.000 claims abstract description 31
238000002156 mixing Methods 0.000 claims abstract description 21
239000003795 chemical substances by application Substances 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 description 73
238000003786 synthesis reaction Methods 0.000 description 73
239000011324 bead Substances 0.000 description 29
150000001413 amino acids Chemical class 0.000 description 20
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical group 0.000 description 19
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 15
239000007795 chemical reaction product Substances 0.000 description 11
239000000463 material Substances 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000000047 product Substances 0.000 description 8
230000002068 genetic effect Effects 0.000 description 7
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
238000002515 oligonucleotide synthesis Methods 0.000 description 5
239000011148 porous material Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
239000011521 glass Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
241000894007 species Species 0.000 description 4
239000013598 vector Substances 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
241000024188 Andala Species 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
229940104302 cytosine Drugs 0.000 description 3
-1 dimethoxytrityl Chemical group 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
230000008569 process Effects 0.000 description 3
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
238000011166 aliquoting Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002981 blocking agent Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003541 multi-stage reaction Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000013638 trimer Substances 0.000 description 1
229940035893 uracil Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

IL9926191A 1990-08-24 1991-08-21 Methods for the synthesis of oligonucleotides with codon triplets with random codon pairs IL99261A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US57364890A	1990-08-24	1990-08-24

Publications (2)

Publication Number	Publication Date
IL99261A0 IL99261A0 (en)	1992-07-15
IL99261A true IL99261A (en)	1996-09-12

Family

ID=24292837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9926191A IL99261A (en)	1990-08-24	1991-08-21	Methods for the synthesis of oligonucleotides with codon triplets with random codon pairs

Country Status (11)

Country	Link
EP (1)	EP0544809B1 (fr)
JP (2)	JP3306063B2 (fr)
AT (1)	ATE174598T1 (fr)
AU (1)	AU8505191A (fr)
CA (1)	CA2089362C (fr)
DE (1)	DE69130647T2 (fr)
IE (1)	IE66123B1 (fr)
IL (1)	IL99261A (fr)
NZ (1)	NZ239498A (fr)
TW (1)	TW217416B (fr)
WO (1)	WO1992003461A1 (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5498538A (en) *	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
US5747334A (en) *	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5639603A (en) *	1991-09-18	1997-06-17	Affymax Technologies N.V.	Synthesizing and screening molecular diversity
US5770358A (en) *	1991-09-18	1998-06-23	Affymax Technologies N.V.	Tagged synthetic oligomer libraries
CA2133554C (fr) *	1992-04-15	2009-07-14	David R. Shortle	Synthese de collections diverses et utiles d'oligonucleotides
WO1994011496A1 (fr) *	1992-11-10	1994-05-26	Ixsys, Inc.	Peptides solubles possedant une conformation secondaire contrainte en solution et procede de preparation de ces composes
BR9407947A (pt) *	1993-11-02	1996-11-26	Affymax Tech Nv	Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
US6165778A (en) *	1993-11-02	2000-12-26	Affymax Technologies N.V.	Reaction vessel agitation apparatus
US5503805A (en) *	1993-11-02	1996-04-02	Affymax Technologies N.V.	Apparatus and method for parallel coupling reactions
US5587471A (en) *	1994-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	Method of making oligonucleotide libraries
US6995017B1 (en)	1994-02-17	2006-02-07	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) *	1996-03-25	2000-12-26	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en)	1994-02-17	2002-05-28	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6406855B1 (en)	1994-02-17	2002-06-18	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en)	1995-02-17	2002-01-01	Maxygen, Inc.	Methods and compositions for polypeptide engineering
US5604097A (en) *	1994-10-13	1997-02-18	Spectragen, Inc.	Methods for sorting polynucleotides using oligonucleotide tags
US5695934A (en) *	1994-10-13	1997-12-09	Lynx Therapeutics, Inc.	Massively parallel sequencing of sorted polynucleotides
US5717085A (en) *	1994-11-23	1998-02-10	Terrapin Technologies, Inc.	Process for preparing codon amidites
US5622699A (en) *	1995-09-11	1997-04-22	La Jolla Cancer Research Foundation	Method of identifying molecules that home to a selected organ in vivo
US6743892B1 (en)	1995-09-11	2004-06-01	La Jolla Cancer Research Foundation	Molecules that home to a selected organ in vivo
JP3900305B2 (ja) *	1995-09-11	2007-04-04	ザバーナムインスティテュート	インビボにおいて選択された器官または組織に帰巣する分子および同分子を同定する方法
US6068829A (en) *	1995-09-11	2000-05-30	The Burnham Institute	Method of identifying molecules that home to a selected organ in vivo
US6506602B1 (en)	1996-03-25	2003-01-14	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en)	1996-03-25	2000-08-01	Maxygen, Inc.	Method for directing evolution of a virus
US6576239B1 (en)	1996-09-10	2003-06-10	The Burnham Institute	Angiogenic homing molecules and conjugates derived therefrom
US6153410A (en) *	1997-03-25	2000-11-28	California Institute Of Technology	Recombination of polynucleotide sequences using random or defined primers
EP1030861A4 (fr)	1997-10-31	2001-09-05	Maxygen Inc	Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
US6537746B2 (en)	1997-12-08	2003-03-25	Maxygen, Inc.	Method for creating polynucleotide and polypeptide sequences
US7390619B1 (en)	1998-02-11	2008-06-24	Maxygen, Inc.	Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en)	1998-02-11	2003-04-01	Maxygen, Inc.	Antigen library immunization
US6232287B1 (en)	1998-03-13	2001-05-15	The Burnham Institute	Molecules that home to various selected organs or tissues
US6365408B1 (en)	1998-06-19	2002-04-02	Maxygen, Inc.	Methods of evolving a polynucleotides by mutagenesis and recombination
AU3391900A (en)	1999-03-05	2000-09-21	Maxygen, Inc.	Encryption of traits using split gene sequences
CN1109185C (zh) *	1999-06-14	2003-05-21	深圳市怡诺威实业发展有限公司	免拆式汽车发动机保养设备
EP1240319A1 (fr) *	1999-12-15	2002-09-18	Genentech, Inc.	Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
WO2001055451A1 (fr)	2000-01-28	2001-08-02	Linden Technologies, Inc.	Nucleotides monomeres proteges en c-3' et synthese d'oligonucleotides sur un support solide
US20040170955A1 (en)	2000-09-08	2004-09-02	Wadih Arap	Human and mouse targeting peptides identified by phage display
US7420030B2 (en)	2000-09-08	2008-09-02	The Board Of Regents Of The University Of Texas System	Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en)	2001-09-07	2008-11-18	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides against placenta and adipose tissues
WO2003078623A1 (fr)	2002-03-19	2003-09-25	Fujitsu Limited	Molecule fonctionnelle et son procede de production
US7544767B2 (en)	2002-04-05	2009-06-09	Burnham Institute For Medical Research	HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
CA2488441C (fr)	2002-06-03	2015-01-27	Genentech, Inc.	Bibliotheques de phages et anticorps synthetiques
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
CN103145842A (zh)	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
JP2010502224A (ja)	2006-09-08	2010-01-28	アボット・ラボラトリーズ	インターロイキン１３結合タンパク質
EP2214708A4 (fr)	2007-10-26	2011-01-12	Centocor Ortho Biotech Inc	Vecteurs, cellules hôtes, procédés de production et utilisations
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2116556B1 (fr)	2008-05-09	2016-03-23	AbbVie Deutschland GmbH & Co KG	Anticorps contre récepteur de produit terminal de glycosylation (RAGE) et utilisations associées
CA2726087A1 (fr)	2008-06-03	2009-12-10	Tariq Ghayur	Immunoglobulines a deux domaines variables et leurs utilisations
TW201006485A (en)	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CN102149825B (zh)	2008-07-08	2015-07-22	Abbvie公司	前列腺素e2双重可变结构域免疫球蛋白及其用途
EP2391652A4 (fr)	2009-01-29	2013-01-02	Abbott Lab	Protéines de liaison à il-1
TWI541021B (zh)	2009-03-05	2016-07-11	艾伯維有限公司	Ｉｌ－１７結合蛋白
BR112012004546A8 (pt)	2009-08-29	2017-12-05	Abbott Lab	Terapêutica por proteínas ligantes dll4-ligantes
WO2011028811A2 (fr)	2009-09-01	2011-03-10	Abbott Laboratories	Immunoglobulines à double domaine variable et leurs utilisations
BR112012008833A2 (pt)	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (fr)	2009-10-31	2011-05-05	Abbott Laboratories	Anticorps pour récepteur pour produits terminaux de glycation avancée (rage) et utilisations de ceux-ci
KR101853278B1 (ko)	2010-03-02	2018-05-02	애브비 인코포레이티드	치료학적 ｄｌｌ４ 결합 단백질
AR081246A1 (es)	2010-05-14	2012-07-18	Abbott Lab	Proteinas de union a il-1
EP3252072A3 (fr)	2010-08-03	2018-03-14	AbbVie Inc.	Immunoglobuline à double domaine variable et ses utilisations
WO2012024650A2 (fr)	2010-08-19	2012-02-23	Abbott Laboratories	Anticorps anti-ngf et leur utilisation
JP2013539364A (ja)	2010-08-26	2013-10-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
TW201307388A (zh)	2010-12-21	2013-02-16	Abbott Lab	Ｉｌ－１結合蛋白
HK1200322A1 (en)	2011-10-24	2015-08-07	Abbvie Inc.	Immunobinders directed against sclerostin
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
CA2875783C (fr)	2012-06-06	2018-12-11	Zoetis Llc	Anticorps anti-ngf caninises et procedes associes
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
US9200073B2 (en)	2012-08-31	2015-12-01	Immunogen, Inc.	Diagnostic assays and kits for detection of folate receptor 1
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
US9550986B2 (en)	2012-12-21	2017-01-24	Abbvie Inc.	High-throughput antibody humanization
WO2014143343A1 (fr)	2013-03-14	2014-09-18	Abbott Laboratories	Anticorps monoclonaux à domaine de liaison à un lipide du cœur de vhc
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
MX362075B (es)	2013-03-14	2019-01-07	Abbott Lab	Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
WO2014144280A2 (fr)	2013-03-15	2014-09-18	Abbvie Inc.	Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
GB201406767D0 (en)	2014-04-15	2014-05-28	Cancer Rec Tech Ltd	Humanized anti-Tn-MUC1 antibodies anf their conjugates
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
US11208474B2 (en)	2016-11-16	2021-12-28	Janssen Biotech, Inc.	Method of treating psoriasis with anti-IL23 specific antibody
EP3544628A4 (fr)	2016-11-23	2020-11-18	Immunoah Therapeutics, Inc.	Protéines de liaison à 4-1bb et leurs utilisations
EP3565845A4 (fr)	2017-01-06	2020-10-07	Biosion, Inc.	Anticorps erbb2 et leurs utilisations
WO2018140121A1 (fr)	2017-01-30	2018-08-02	Janssen Biotech, Inc.	Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MX2019009377A (es)	2017-02-07	2019-12-11	Janssen Biotech Inc	Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
EP3625254B1 (fr)	2017-07-31	2023-12-13	F. Hoffmann-La Roche AG	Procédé d'humanisation fondé sur une structure tridimensionnelle
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3694552A1 (fr)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anticorps anti-lap et leurs utilisations
JP2021502349A (ja)	2017-11-06	2021-01-28	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
KR20250139415A (ko)	2018-02-14	2025-09-23	호라이즌 테라퓨틱스 아일랜드 디에이씨	고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
MX2020009265A (es)	2018-03-05	2020-10-01	Janssen Biotech Inc	Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
BR112020017701A2 (pt)	2018-03-12	2020-12-29	Zoetis Services Llc	Anticorpos anti-ngf e métodos dos mesmos
US20200025776A1 (en)	2018-07-18	2020-01-23	Janssen Biotech, Inc.	Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
IL326284A (en)	2018-09-24	2026-04-01	Janssen Biotech Inc	A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
CN113164780A (zh)	2018-10-10	2021-07-23	泰洛斯治疗公司	抗lap抗体变体及其用途
IL283192B2 (en)	2018-11-20	2025-10-01	Janssen Biotech Inc	A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
MA54562A (fr)	2018-12-18	2021-10-27	Janssen Biotech Inc	Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
WO2020183269A1 (fr)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
KR20210141998A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물의 제조 방법
EA202192505A1 (ru)	2019-03-14	2022-03-29	Янссен Байотек, Инк.	Способы получения композиций антитела к фно
EP3938384A4 (fr)	2019-03-14	2022-12-28	Janssen Biotech, Inc.	Méthodes de fabrication permettant de produire des compositions d'anticorps anti-il12/il23
JP2022526493A (ja)	2019-03-18	2022-05-25	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
JP7805788B2 (ja)	2019-05-23	2026-01-26	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
MA56124A (fr)	2019-06-04	2022-04-13	Janssen Biotech Inc	Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
US20210347880A1 (en)	2020-05-05	2021-11-11	Janssen Biotech, Inc.	Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL298389A (en)	2020-05-21	2023-01-01	Janssen Biotech Inc	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022013745A1 (fr)	2020-07-13	2022-01-20	Janssen Biotech, Inc.	Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
US20220073603A1 (en)	2020-07-30	2022-03-10	Janssen Biotech, Inc.	Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
BR112023017490A2 (pt)	2021-03-17	2023-11-07	Receptos Llc	Métodos de tratamento de dermatite atópica com anticorpos anti il-13
US12534524B2 (en)	2021-07-09	2026-01-27	Janssen Biotech, Inc.	Manufacturing methods for producing anti-TNF antibody compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4458066A (en) *	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
CA2009996A1 (fr) *	1989-02-17	1990-08-17	Kathleen S. Cook	Procede de production de genes encodant des polymeres aleatoires d'acides amines

1991
- 1991-08-20 JP JP51511591A patent/JP3306063B2/ja not_active Expired - Fee Related
- 1991-08-20 AU AU85051/91A patent/AU8505191A/en not_active Abandoned
- 1991-08-20 DE DE69130647T patent/DE69130647T2/de not_active Expired - Fee Related
- 1991-08-20 CA CA002089362A patent/CA2089362C/fr not_active Expired - Fee Related
- 1991-08-20 EP EP91916483A patent/EP0544809B1/fr not_active Expired - Lifetime
- 1991-08-20 AT AT91916483T patent/ATE174598T1/de active
- 1991-08-20 WO PCT/US1991/005939 patent/WO1992003461A1/fr not_active Ceased
- 1991-08-21 IL IL9926191A patent/IL99261A/en not_active IP Right Cessation
- 1991-08-22 NZ NZ239498A patent/NZ239498A/en unknown
- 1991-08-23 IE IE299391A patent/IE66123B1/en not_active IP Right Cessation
- 1991-09-26 TW TW080107638A patent/TW217416B/zh active
2001
- 2001-03-15 JP JP2001075101A patent/JP2001299342A/ja active Pending

Also Published As

Publication number	Publication date
EP0544809B1 (fr)	1998-12-16
JP2001299342A (ja)	2001-10-30
JP3306063B2 (ja)	2002-07-24
WO1992003461A1 (fr)	1992-03-05
IE912993A1 (en)	1992-02-26
DE69130647D1 (de)	1999-01-28
CA2089362C (fr)	2000-11-21
AU8505191A (en)	1992-03-17
TW217416B (fr)	1993-12-11
NZ239498A (en)	1993-07-27
IL99261A0 (en)	1992-07-15
EP0544809A4 (en)	1994-08-17
CA2089362A1 (fr)	1992-02-25
IE66123B1 (en)	1995-12-13
JPH06503809A (ja)	1994-04-28
ATE174598T1 (de)	1999-01-15
DE69130647T2 (de)	1999-05-06
EP0544809A1 (fr)	1993-06-09

Legal Events

Date	Code	Title
1997-02-18	FF	Patent granted
1997-06-10	KB	Patent renewed
1998-01-04	KB	Patent renewed
2001-10-31	KB	Patent renewed
2005-11-20	KB	Patent renewed
2010-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0544809B1 (fr)	1998-12-16	Procede de production par synthese d'oligonucleotides ayant des codons aleatoires
US5523388A (en)	1996-06-04	Methods of synthesizing oligonucleotides with random codons
Ike et al.	1983	Solid phase synthesis of polynucleotides. VIII. Synthesis of mixed oligodeoxyribonucleotides by the phosphotriester solid phase method
EP0794001B1 (fr)	2000-10-11	Système automatique pour la synthèse et purification de polynucléotides
US5175209A (en)	1992-12-29	Porous wafer for segmented synthesis of biopolymers
US6001993A (en)	1999-12-14	Random oligonucleotide libraries and methods of making the same
IE913424A1 (en)	1992-04-08	Surface expression libraries of randomized peptides
CA2749227A1 (fr)	2005-01-13	Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
EP0344177B1 (fr)	1994-05-11	Plaquette gaufree poreuse pour la synthese segmentee de biopolymeres
WO2000018778A9 (fr)	2000-06-08	Synthese d'acides nucleiques fondee sur une generation aleatoire de codons
WO1999051547A2 (fr)	1999-10-14	Synthese en phase solide de composes organiques au moyen de reactifs de phosphitylation
Adhin et al.	1990	Complete nucleotide sequence of the group I RNA bacteriophage fr
Khudyakov et al.	2002	Artificial DNA: Methods and applications
van Huijsduijnen et al.	1992	A means to reduce the complexity of oligonucleotides encoding degenerate peptides
Fiers et al.	1969	Studies on the primary structure and the replication mechanism of bacteriophage RNA
US6350595B1 (en)	2002-02-26	Synthesis of polynucleotides having random sequences
Pon	2002	Chemical Synthesis of Oligonucleotides: From Dreams to Automation
WO1997047768A1 (fr)	1997-12-18	Procede de synthese aleatoire de biopolymeres
WO2022161450A1 (fr)	2022-08-04	Procédé de mesure d'une activité de réaction relative et procédé de conception d'une réaction de synthèse d'oligonucléotides
Treiber et al.	1995	A simple method for preparing pools of synthetic oligonucleotides with random point deletions
JP3028814B2 (ja)	2000-04-04	生体高分子の分割合成のための多孔質ウエハー